Prelude’s JAK2 V617F inhibitor PRT-12396 gains IND clearance

Feb. 4, 2026

Prelude Therapeutics Inc. has received IND clearance from the FDA for PRT-12396, a mutant-selective JAK2 V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms.

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...